Endorsed NICE Guidance 2011-2012
The following NICE Technology Appraisals were endorsed during 2011-12 using the new process that came into effect on 28 September 2011. The circulars outlining this process and the previous process can be found on our homepage
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Fully Endorsed
March 2012
- TA 70 Imatinib for the treatment of chronic myeloid leukaemia
- TA 246 Pharmalgen for the treatment of systemic reactions to bee and wasp venom allergy
- TA 247 Tocilizumab for the treatment of rheumatoid arthritis
- TA 248 Exenatide (prolonged-release for the treatment of type 2 diabetes
February 2012
- TA61 - Capecitabine and tegafur uracil for metastatic colorectal cancer
- TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer
- TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
- TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (review)
- TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma (Review of NICE TA110)
- TA244 - Roflumilast for the management of severe chronic obstructive pulmonary disease
- TA245 - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
January 2012
- TA237 - Ranibizumab for the treatment of diabetic macular oedema
- TA238 - Tocilizumab for the Treatment of Systematic Idiopathic Juvenile Arthritis
- TA239 - Fulvestrant for the treatment of locally advanced or metastatic breast cancer
December 2011
- TA186 - Certolizumab Pegol for the treatment of Rheumatoid Arthritis
- TA197 - Dronedarone for the Treatment of Non-Permanent Atrial Fibrillation
- TA199 - Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis
- TA203 - Liraglutide for the Treatment of Type II Diabetes Mellitus
- TA218 - Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
- TA219 - Everolimus for the second-line treatment of metastatic renal cell carcinoma
- TA220 - Golimumab for the treatment of psoriatic arthritis
- TA225 - Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
- TA233 - Golimumab for the treatment of ankylosing spondylitis
November 2011
- TA166 - Hearing Impairment - cochlear implants for severe to profound deafness in children and adults
- TA169 - Sunitinib for the Treatment of Renal Cell Carcinoma (related to TA215)
- TA185 - Trabectedin for the Treatment of Advanced Soft Tissue Sarcoma
- TA188 - Human growth hormone (somatropin) for the treatment of growth failure in children (review)
- TA190 - Pemetrexed for the maintenance treatment of non-small-cell lung cancer
- TA193 - Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukaemia
- TA195 - Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for Treatment of Rheumatoid Arthritis after failure of a TNF inhibitor
- TA198 - Tocizilumab for rheumatoid arthritis Please note that this appraisal has been updated and replaced by TA 247
- TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
- TA215 - Pazopanib for the First-line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma (related to TA169)
- TA216 - Bendamustine for the treatment of chronic lymphocytic leukaemia
- TA221 - Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura
- TA222 - Trabectedin for the treatment of relapsed ovarian cancer
- TA223 - Cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
- TA226 - Ritixumab for the maintenance treatment of follicular non-Hodgkin's lymphoma following response to first-line chemotherapy
- TA227 - Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
- TA228 - Bortezomib and Thalidomide for the first-line treatment of multiple myeloma
- TA229 - Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO)
- TA230 - Bivalirudin for the treatment of ST-segment elevation myocardial infarction (STEMI)
- TA232 - Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
- TA234 - Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs
- TA235 - Mifamurtide for the treatment of osteosarcoma
- TA236 - Ticagrelor for the treatment of acute coronary syndromes
Endorsed With Caveats
November 2011
This guidance has been partially updated by ‘Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C’ NICE Technology Appraisal guidance TA200. The elements of TA75 which have been updated and replaced are:
- section 1.2, bullet 3 only;
- section 1.4 of TA75 for adults who are eligible for shortened courses of combination therapy (as described in section 1.2 of TA200);
- section 1.7, bullet 1 only.
- All other recommendations in TA75 still stand.
It should be noted that continued therapy should be carefully reconsidered in a patient not responding to infliximab and adalimumab in the treatment of Crohn’s disease in accordance with the time period set out in the respective manufacturers’ Summary of Product Characteristics.
In June 2011, sections 3.11, 3.12 and 4.1.5 of the guidance were amended to correct an error in the stated dose of ribavirin. The doses of ribavirin should be in mg (milligrams), and not micrograms. Any copies of the guidance printed before this date should be destroyed.
Not Endorsed as Applicable to Northern Ireland
None
ENDORSED UNDER PREVIOUS PROCESS
The following NICE Technology Appraisals were endorsed by DHSSPS during 2011-12 under the process which was in place prior to 28 September 2011
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA86 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (NOTE: This guidance has been partially updated by TA209)
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA191 - Capecitabine for the treatment of Advanced Gastric Cancer
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA192 - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA201 - Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children aged 6-12 Years
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA202 - Ofatumumab for the Treatment of Chronic Lymphocytic Leukaemia Refractory to Fludarabine and Alemtuzumab
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA204 - Denosumab for the Prevention of Osteoporotic Fractures in Postmenopausal Women
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA205 - Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA209 - Imatinib for the treatment of unresectable and / or metastatic Gastrointestinal Stromal Tumours (Part update of NICE TA86)
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA212 - Colorectal Cancer (metastatic) - Bevacizumab in combination with Oxaliplatin & either 5-fluorouracil plus Folinic Acid or Capecitabine
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA213 - Aripiprazole for Schizophrenia in People Aged 15-17 Years
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA214 - Bevacizumab in Combination with a Taxane for the First-line Treatment of Metastatic Breast Cancer
- National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA217 - Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease
